Glecaprevir / PibrentasvirBrand Name: Mavyret Other Names: GLE / PIB Drug Class: Opportunistic Infections and Coinfections
What is Mavyret?
Mavyret is anprescription medicine approved by the U.S. (FDA) for the treatment of chronic (HCV) in people who meet certain requirements, as determined by a health care provider.
HCV is an What is an Opportunistic Infection? fact sheet.(OI) of HIV. An OI is an that occurs more frequently or is more severe in people with weakened immune systems—such as people with HIV—than in people with healthy immune systems. To learn more about OIs, read the
To learn how HIV and HCV are connected, read the AIDSinfo HIV and Hepatitis C fact sheet. The fact sheet includes information about how HCV is spread, symptoms of HCV, and treatment options.
How is Mavyret used in people with HIV?
The Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents include recommendations on the use of Mavyret in people with HIV.
Using a medicine as indicated on the medicine label is calledThe guidelines include recommendations on the following uses of Mavyret: ; using the medicine in a different way is called . Off-label use, for example, can include using a drug for a different disease or medical condition. Good medical practice and the best interests of a patient sometimes require that a medicine be used off-label.
- On-label use: treatment of chronic HCV
- Off-label use: treatment of acute HCV
This may not include all of the HIV-related uses of Mavyret recommended in the guidelines. Some recommended uses, such as uses in certain rare circumstances, may have been omitted.
What should I tell my health care provider before taking Mavyret?
Before taking Mavyret, tell your health care provider:
- If you are allergic to any of the medicines in Mavyret (glecaprevir and pibrentasvir) or any other medicines.
- About any medical conditions you have or have had, including (HBV) or problems other than HCV.
- If you have had a liver or a kidney transplant.
- About anything that could affect your ability to take medicines, such as difficulty swallowing or remembering to take tablets.
- If you are pregnant or plan to become pregnant. Whether Mavyret can harm an unborn baby is unknown. Talk to your health care provider about possible risks with taking Mavyret when pregnant.
- If you are breastfeeding or plan to breastfeed. Do not breastfeed if you have HIV.
- About other prescription and nonprescription medicines, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Mavyret may affect the way other medicines or products work, and other medicines or products may affect how Mavyret works. Ask your health care provider if there are interactions between Mavyret and the other medicines you take.
Ask your health care provider about possible side effects from Mavyret. Your health care provider will tell you what to do if you have side effects.
How should I take Mavyret?
Take Mavyret according to your health care provider’s instructions. Your health care provider will tell you how much Mavyret to take and when to take it. Before you start Mavyret and each time you get a refill, read any printed information that comes with your medicine.
How should Mavyret be stored?
- Store Mavyret at or below 86°F (30°C).
- Keep Mavyret in its original blister package until you are ready to take it.
- Do not use Mavyret if the seal on top of the carton of blister packages is broken or missing.
- Throw away Mavyret that is no longer needed or expired (out of date). Follow FDA guidelines on how to safely dispose of unused medicine.
- Keep Mavyret and all medicines out of reach of children.
Where can I find more information about Mavyret?
More information about Mavyret is available:
- Recommendations on the HIV-related uses of Mavyret, from the Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents, prepared by the , the , and the HIV Medicine Association of the Diseases Society of America
- Mavyret-related research studies, from the AIDSinfo database of study summaries
The above Patient Version drug summary is based on the following FDA label(s): Tablet, film-coated.
Last Reviewed: December 13, 2018